38 recruiting, 26 active not recruiting, 25 completed, 15 terminated. 61 Phase 2, 32 Not applicable, 29 Phase 1, 16 Phase 3, 3 Early Phase 1.
Follow SABR: new trials by email Literature Review of SABR trials Research Report on SABR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-09-03 |
| Using an Artificial Intelligence Software Tool (iSeg) During Radiation Treatment Planning for Patients With Lung Tumors Artificial Intelligence-based Intervention, Best Practice, Computed Tomography - Lung Carcinoma, Lung Non-Small Cell Carcinoma | Not applicable | Not yet recruiting | Northwestern University | 34 | 2027-02-13 | 2026-10-27 |
| Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer Biospecimen Collection, Computed Tomography, Lymph Node Biopsy - Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 2 | Recruiting | Roswell Park Cancer Institute | 200 | 2026-09-01 | 2026-08-26 |
| A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy - Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain | Phase 1 | Recruiting | City of Hope Medical Center | 6 | 2026-09-01 | 2026-10-19 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma axitinib plus toripalimab, SABR - Oligometastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 48 | 2026-08-15 | 2026-08-04 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide - Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 107 | 2025-12-12 | 2026-09-17 |
| Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management SABR - Breast Cancer Female | Not applicable | Recruiting | University of Kansas Medical Center | 18 | 2025-11-04 | 2026-02-10 |
| Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer Stereotactic Body Radiation Therapy (SBRT) - Prostate CA | Phase 2 | Recruiting | British Columbia Cancer Agency | 100 | 2025-09-04 | 2026-06-24 |
| SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors SABR - Breast Cancer, Metastases | Not applicable | Not yet recruiting | British Columbia Cancer Agency | 40 | 2025-07-01 | 2025-04-24 |
| Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer Biopsy, Biospecimen Collection, Bone Scan - Breast Carcinoma, Colorectal Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 24 | 2025-05-27 | 2026-10-05 |
| Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial Best Practice, Biospecimen Collection, Bone Metastases Treatment - Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm | Phase 3 | Active not recruiting | NRG Oncology | 280 | 2025-05-07 | 2026-08-17 |
| Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer Serplulimab, Chemotherapy, SABR - Advanced Colorectal Carcinoma, Immunotherapy | Phase 2 | Recruiting | Fudan University | 208 | 2025-03-01 | 2025-03-14 |
| Total RadIoTherapy of Oligometastatic caNcerS stereotactic ablative radiotherapy - Oligometastatic Malignant Solid Neoplasm | Phase 3 | Recruiting | University of California, San Diego | 300 | 2024-11-12 | 2026-10-16 |
| Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma Biospecimen Collection, Computed Tomography, Osimertinib - Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Suspended | City of Hope Medical Center | 32 | 2024-10-21 | 2026-10-20 |
| Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) Pembrolizumab, Folfirinox, SABR - Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Amsterdam UMC, location VUmc | 66 | 2024-09-23 | 2026-02-13 |
| Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer Computed Tomography, Cone-Beam Computed Tomography, Image-Guided Adaptive Radiation Therapy - Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Not applicable | Recruiting | Mayo Clinic | 164 | 2024-08-15 | 2026-10-14 |
| Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 18 | 2024-07-23 | 2026-10-07 |
Showing 20 of 130. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (26) · Prostatic Neoplasms (23) · Lung Neoplasms (16) · Neoplasm Metastasis (13) · Squamous Cell Carcinoma of Head and Neck (10) · Breast Neoplasms (9) · Carcinoma, Renal Cell (9) · Carcinoma, Hepatocellular (5) · Colorectal Neoplasms (4) · Melanoma (4) · Oropharyngeal Neoplasms (4) · Mouth Neoplasms (3) · Adenocarcinoma of Lung (2) · Brain Neoplasms (2) · Carcinoma (2)
M.D. Anderson Cancer Center (15) · Jonsson Comprehensive Cancer Center (11) · City of Hope Medical Center (10) · University of Texas Southwestern Medical Center (9) · Mayo Clinic (8) · NRG Oncology (6) · National Cancer Institute (NCI) (5) · British Columbia Cancer Agency (4) · Roswell Park Cancer Institute (4) · Amsterdam UMC, location VUmc (3) · University of Washington (3) · Institute of Cancer Research, United Kingdom (2) · Northwestern University (2) · OHSU Knight Cancer Institute (2) · Peter MacCallum Cancer Centre, Australia (2)
United States (91) · Canada (15) · China (7) · Australia (6) · Netherlands (4) · United Kingdom (4) · Belgium (3) · Hong Kong (3) · Ireland (3) · Italy (3) · Switzerland (3) · France (2) · Norway (2) · Spain (2) · Denmark (1)
Amar Kishan (4) · Arya Amini (3) · James Welsh (3) · Raquibul Hannan, MD, PhD (3) · Amar Kishan, MD (2) · Anurag K Singh (2) · Chad Tang (2) · Sagus Sampath (2) · Shankar Siva, A/Prof (2) · Yvonne M Mowery (2) · A.J. de Langen, MD, PhD (1) · Abraham Alexander (1) · Alan C Lee (1) · Alejandro Sanchez (1) · Alfonso Gomez-Iturriaga, MD, PhD (1)
PMID 18618604, PMID 19255320, PMID 19255321, PMID 24563870, PMID 26095785, PMID 26104945, PMID 28345951, PMID 29852037, PMID 30286739, PMID 30352550, PMID 31431387, PMID 31996395, PMID 32736936, PMID 33051340, PMID 33096027, PMID 33720067, PMID 34529930, PMID 34717797, PMID 34749885, PMID 34903471, PMID 35617923, PMID 36173619, PMID 36223780, PMID 36306810, PMID 36934894, PMID 37123045, PMID 37419394, PMID 37478883, PMID 37619656, PMID 37707811, PMID 38421243, PMID 38423047, PMID 38494380, PMID 38519913, PMID 39384194, PMID 39615497, PMID 39699905, PMID 40097400, PMID 40152443, PMID 40372727, PMID 40377420, PMID 40714134, PMID 40839922, PMID 40915303, PMID 40950337, PMID 41054436, PMID 41063518, PMID 41223345, PMID 41732215, PMID 41825136
P30CA033572 (9), U10CA180868 (5), P30CA060553 (2), U10CA180821 (2), U10CA180888 (2), UM1CA186690 (2), 2015 (1), 2023 (1), P30CA015704 (1), P30CA016672 (1), P30CA036727 (1), P30CA072720 (1), P30CA093373 (1), P30CA138292 (1), P50CA092131 (1)